SPK Immunosuppression Therapy

Almost three-fourths of 1996-2000 SPK recipients received anti-T-cell agents as induction, regardless of maintenance immunosuppression (Figure 13). Overall pancreas graft survival rates were slightly higher for the Zenapax/Simulect group (89%), particularly for ED cases. For initial maintenance immunosuppression in SPK cases with anti-T cell therapy, pancreas GSRs were significantly higher in those recipients who received MMF versus AZA, whether in combination with CsA or Tac . Without anti-T cell therapy, there was no difference by maintenance immunosuppression (Figure 14a and 14b). Most SPK recipients received anti-T cell therapy plus Tac & MMF (n=1379); GSRs were similar for BD (n=557) and ED (n=801): 85% and 84% respectively (p>0.06).

Figure 14a

Figure 14b